Jane Street’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-25,500
Closed -$115K – 11394
2026
Q1
$115K Sell
25,500
-25,600
-50% -$112K ﹤0.01% 10563
2025
Q4
$246K Buy
+51,100
New +$230K ﹤0.01% 9276
2025
Q2
– Sell
-17,800
Closed -$62.1K – 9492
2025
Q1
$62.1K Buy
+17,800
New +$59.4K ﹤0.01% 8951
2022
Q3
– Sell
-38,000
Closed -$103K – 9601
2022
Q2
$103K Sell
38,000
-187,700
-83% -$480K ﹤0.01% 8617
2022
Q1
$673K Sell
225,700
-39,000
-15% -$119K ﹤0.01% 6925
2021
Q4
$1.03M Buy
264,700
+78,400
+42% +$305K ﹤0.01% 5841
2021
Q3
$799K Buy
186,300
+143,900
+339% +$480K ﹤0.01% 6363
2021
Q2
$128K Sell
42,400
-4,500
-10% -$13.9K ﹤0.01% 9146
2021
Q1
$156K Sell
46,900
-34,800
-43% -$134K ﹤0.01% 8440
2020
Q4
$290K Buy
+81,700
New +$286K ﹤0.01% 6465

Other funds holding ABUS

Jane Street's ABUS Position: Q3 2026 in Review

Jane Street opened a new position in Arbutus Biopharma (ABUS) in Q3 2026: 571,080 shares worth $2.73M. The stake represents ﹤0.01% of the portfolio and ranks #4635 among its holdings. This is a return to the name: Jane Street previously reported a position in ABUS as recently as Q4 2025.

Jane Street first reported a position in ABUS in Q1 2014 and has held it in 28 quarters since. 216 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • Jane Street held 571,080 shares of Arbutus Biopharma worth $2.73M as of Q3 2026.
  • Arbutus Biopharma was a new Jane Street position in Q3 2026.
  • Arbutus Biopharma made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #4635 holding.
  • Jane Street first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 28 quarters since.
  • 216 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.